Showing 2701-2710 of 4063 results for "".
- Clearside Biomedical Announces Data Presentations at the AAO 2020https://modernod.com/news/clearside-biomedical-announces-data-presentations-at-the-aao-2020/2478556/Clearside Biomedical announced that two presentations of Clearside preclinical and clinical data were given at the virtual American Academy Ophthalmology (AAO) 2020 Annual Meeting. Clearside also announced a clinical characterization of the suprachoroidal in
- EyeMD EMR 2.0 All-in-One Platform Unveiled at AAO Virtualhttps://modernod.com/news/eyemd-emr-healthcare-systems-to-unveil-the-eyemd-emr-2-0-all-in-one-platform-at-aao-virtual/2478542/EyeMD EMR Healthcare Systems will debut EyeMD EMR 2.0, an all-in-one EMR, PM, and PACS system at the American Academy of Ophthalmology (AAO) Virtual Conference, taking place Nov. 13–15, 2020. EyeMD EMR 2.0 now includes EMR, PM and PACS functionality in one streamlined offering. EyeMD EMR P
- Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Material Recycled Through One By One Recycling Programhttps://modernod.com/news/bausch-lomb-reports-nearly-27-million-united-of-contact-lens-material-recycled-through-one-by-one-recycling-program/2478541/Bausch + Lomb announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and blister packs since launching in November 2016. The program, made possible through a collaboration with TerraCycle, a leader in the collection and repurposing
- Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on DME at AAO 2020 Virtual Meetinghttps://modernod.com/news/kodiak-sciences-announces-presentation-of-ksi-301-phase-1b-clinical-study-data-focused-on-dme-at-aao-2020-virtual-meeting/2478532/Kodiak Sciences announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Details of the presentation are as follows: Event: Late Breaking D
- Santen to Present Glaucoma/OcularHypertension Data at AAO 2020 Virtualhttps://modernod.com/news/santen-to-present-glaucoma-ocularhypertension-data-at-aao-2020-virtual/2478519/Santen announced that the following talks on glaucoma and ocular hypertension will be presented at the American Academy of Ophthalmology (AAO) Virtual 2020 meeting. Poster Topic: MicroShunt (or DE-128), an investigational surgical glaucoma implant designed to reduce intrao
- Lensar to Present Several Papers at 2020 AAO Virtual Meetinghttps://modernod.com/news/lensar-to-presents-several-papers-at-2020-aao-virtual-meeting/2478513/Lensar announced the following posters/papers were accepted to be presented at the 2020 AAO Virtual Meeting taking place Nov. 13-15. 2020 AAO Accepted Posters/Papers Company Ty
- Allergan to Share New Data at American Academy of Ophthalmology (AAO) 2020 Virtual Meetinghttps://modernod.com/news/allergan-to-share-new-data-at-american-academy-of-ophthalmology-aao-2020-virtual-meeting/2478510/Allergan, which is now part of AbbVie, announced that it will present new data advancing scientific understanding of an IOP-lowering treatment in glaucoma and evaluating an investigational treatment for presbyopia at American Academy of Ophthalmology (AAO) 2020 virtual meeting (November 13-15).</
- New Alcon Innovations in IOLs, Digital Health Solutions to be Showcased at the AAO 2020 Virtual Annual Meetinghttps://modernod.com/news/new-alcon-innovations-in-iols-digital-health-solutions-to-be-showcased-at-the-aao-2020-virtual-annual-meeting/2478506/Alcon will highlight a robust scientific program including new data and advancements across its portfolio of innovations in cataract, refractive and retina surgery during the American Academy of Ophthalmology (AAO) 2020 virtual annual meeting, which takes place November 13-15, 2020, according to
- Oxurion NV Confirms New Patents for THR-687 Issued by European and US Patent Officeshttps://modernod.com/news/oxurion-nv-confirms-new-patents-for-thr-687-issued-by-european-and-us-patent-offices/2478504/Oxurion NV announced a strengthening of its intellectual property (IP) portfolio governing THR-687, an integrin antagonist being developed for the treatment of DME. The European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have both issued new composition-o
- Lineage Cell Therapeutics to Host Expert Call Following OpRegen Data Update at 2020 AAO Meetinghttps://modernod.com/news/lineage-cell-therapeutics-to-host-expert-call-following-opregen-data-update-at-2020-aao-meeting/2478483/Lineage Cell Therapeutics will be hosting a call to discuss updated interim results from the phase 1/2a study of its lead product candidate, OpRegen, with one of the study’s principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for